联邦制药(03933.HK)产品注射用头孢曲松钠通过一致性评价

阿斯达克财经
07 Mar

联邦制药(03933.HK) 公布,其全资附属公司司申报的注射用头孢曲松钠(规格:1.0g;2.0g)经中国国家药品监督管理局审批,通过仿制药质量和疗效一致性评价。
注射用头孢曲松钠是第三代头孢菌素类抗生素,临床适用于治疗敏感致病菌引起的呼吸道感染、腹部感染、肾脏及泌尿道感染、生殖系统感染等,以及术前预防感染。(sl/a)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-07 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10